EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2
INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL
IN PSORIATIC ARTHRITIS

a 2024

EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS

KIVITZ, Alan; Elena Tomaselli MUENSTERMAN; Arthur KAVANAUGH; van der Heijde DESIREE; Piotr A KLIMIUK et al.

Základní údaje

Originální název

EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS

Autoři

Vydání

7th IFPA Conference, 2024

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.700

Kód RIV

RIV/00216224:14160/24:00139095

Organizační jednotka

Farmaceutická fakulta

ISSN

UT WoS

001280297200001

Klíčová slova anglicky

TAK-279; oral TYK2 inhibitor; phase 2B trial; psoriatic arthritis

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam

Změněno: 17. 3. 2025 14:44, Ing. Richard Heger, Ph.D.

Anotace

V originále

TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis. TAK-279 is a highly potent, selective, oral, allosteric TYK2 inhibitor shown to be clinically effective with an acceptable safety profile in a phase 2b trial in patients with moderate-to-severe psoriasis.¹ Objectives: To evaluate efficacy and safety of TAK-279 in patients with active PsA treated over 12 weeks.

Citovat

KIVITZ, Alan; Elena Tomaselli MUENSTERMAN; Arthur KAVANAUGH; van der Heijde DESIREE; Piotr A KLIMIUK; Guillermo VALENZUELA; Eva DOKOUPILOVÁ; Gabrielle POIRIER; Bhaskar SRIVASTAVA; Sue DASEN; Xinyan ZHANG; Mona TRIVEDI; Haoling Holly WENG; Ting HONG; Peter POTHULA a Xenofon BARALIAKOS. EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS. In 7th IFPA Conference. 2024. ISSN 0001-5555.

@proceedings{2484819,
   author = {Kivitz, Alan and Muensterman, Elena Tomaselli and Kavanaugh, Arthur and Desiree, van der Heijde and Klimiuk, Piotr A and Valenzuela, Guillermo and Dokoupilová, Eva and Poirier, Gabrielle and Srivastava, Bhaskar and Dasen, Sue and Zhang, Xinyan and Trivedi, Mona and Weng, Haoling Holly and Hong, Ting and Pothula, Peter and Baraliakos, Xenofon},
   booktitle = {7th IFPA Conference},
   keywords = {TAK-279; oral TYK2 inhibitor; phase 2B trial; psoriatic arthritis},
   language = {eng},
   title = {EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS},
   url = {https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001},
   year = {2024}
}

TY  - CONF
ID  - 2484819
AU  - Kivitz, Alan - Muensterman, Elena Tomaselli - Kavanaugh, Arthur - Desiree, van der Heijde - Klimiuk, Piotr A - Valenzuela, Guillermo - Dokoupilová, Eva - Poirier, Gabrielle - Srivastava, Bhaskar - Dasen, Sue - Zhang, Xinyan - Trivedi, Mona - Weng, Haoling Holly - Hong, Ting - Pothula, Peter - Baraliakos, Xenofon
PY  - 2024
TI  - EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
KW  - TAK-279
KW  - oral TYK2 inhibitor
KW  - phase 2B trial
KW  - psoriatic arthritis
UR  - https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001
N2  - TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis. TAK-279 is a highly potent, selective, oral, allosteric TYK2 inhibitor shown to be clinically effective with an acceptable safety profile in a phase 2b trial in patients with moderate-to-severe psoriasis.¹ Objectives: To evaluate efficacy and safety of TAK-279 in patients with active PsA treated over 12 weeks.
ER  -

Přehled o publikaci